ストックスクリーナーアプリを入手
16.05
1.97%
0.31
プレマーケット:
15.95
-0.10
-0.62%
Viatris Inc (VTRS) 最新ニュース
UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade - Insider Monkey
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
(VTRS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Why Viatris Inc (VTRS) May Struggle to Outperform: A Look at Fut - GuruFocus
How Do Investors Really Feel About Viatris Inc? - Sahm
Can Viatris Inc. sustain its profitabilityJuly 2025 Levels & Daily Chart Pattern Signals - mfd.ru
Where is Viatris Inc. (VTRS) headed according to the Street? - MSN
Is Viatris Inc. impacted by rising ratesWeekly Trend Summary & Technical Confirmation Alerts - mfd.ru
Is Viatris (VTRS) Quietly Repositioning Its Deal-Making Strategy With a New Chief Legal Officer? - simplywall.st
Viatris (VTRS) Shares Cross 3% Yield Mark - Nasdaq
Viatris Continues Support of SBP, Celebrates Restoration of 250th Home Damaged by Hurricane Maria - CSRwire
Viatris Inc. stock rises Monday, outperforms market - MSN
JPMorgan Adjusts Price Target on Viatris to $16 From $14, Maintains Neutral Rating - marketscreener.com
Viatris stock hits 52-week high at $15.61 By Investing.com - Investing.com Australia
Chris Davis's Strategic Acquisition of Viatris Inc. Shares - GuruFocus
Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse - FinancialContent
Viatris stock hits 52-week high at $15.61 - Investing.com
Indiana wins $6.25 million in settlement with pharmaceutical companies - starcitytv.com
Where is Viatris Inc. (VTRS) Headed According to the Street? - Finviz
Viatris Septerna BIO Takeda name new legal chiefs - BioXconomy
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Viatris (VTRS) - The Globe and Mail
Viatris 2022 Sustainability Report: Building Foundations To Advance Diversity, Equity and Inclusion - CSRwire
Why Viatris (VTRS) Stock Is Up Today - The Globe and Mail
Viatris Stock Hits 52-Week High After UBS Buy Rating & $18 Price Target | Market Update 2026News and Statistics - IndexBox
Why Viatris (VTRS) Shares Are Rising Today - Bitget
Viatris gains as UBS upgrades to buy on outlook and pipeline - MSN
Indiana reaches $6.25M settlement with pharmaceutical companies over EpiPen prices - Indianapolis Business Journal
Viatris gains as UBS upgrades to Buy (VTRS:NASDAQ) - Seeking Alpha
US drugmaker Viatris appoints in-house pharma veteran as next CLO - The Global Legal Post
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Viatris Shares Rise After UBS Upgrade - marketscreener.com
UBS Upgrades Viatris to Buy From Neutral, Adjusts Price Target to $18 From $11 - marketscreener.com
A Look At Viatris (VTRS) Valuation After The New Chief Legal Officer Appointment - Yahoo Finance
Is Viatris’ New Deal-Tested CLO a Turning Point in Its Transformation Strategy (VTRS)? - simplywall.st
Responsive Playbooks and the VTRS Inflection - Stock Traders Daily
Inflation Data: Is Viatris Inc impacted by rising ratesMarket Activity Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
What are Wall Street analysts' target price for Viatris stock? - MSN
Viatris Announces Chief Legal Officer Transition and Successor - The Globe and Mail
Viatris Inc (VTRS) Stock Price Up 5.3% on Feb 4 - GuruFocus
Viatris Appoints Matthew J. Maletta as Chief Legal Officer - The Malaysian Reserve
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 - Sahm
Viatris to Report Fourth Quarter and Full Year 2025 Financial Re - GuruFocus
Viatris stock hits 52-week high at $13.49 By Investing.com - Investing.com Nigeria
1.32%
1.05%
大文字化:
|
ボリューム (24 時間):